REG - Allergy Therapeutics - Further detail from G306 Phase III field trial

Allergy TherapeuticsAnnouncement

07/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240507:nRSG3370Na&default-theme=true

RNS Number : 3370N  Allergy Therapeutics PLC  07 May 2024

 

 Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

 

Allergy Therapeutics provides further detail from positive top line results
from G306 Phase III field trial to evaluate efficacy and safety of Grass MATA
MPL

 

-     Statistically significant reduction in Combined Symptom Medication
Score (CSMS) seen in active treatment group compared to placebo

 

-     Sensitivity analyses of primary endpoint and secondary endpoints
show high consistency with primary endpoint results

 

-     The Group is preparing marketing authorisation application (MAA) for
planned submission in Q4 2024

 

7 May 2024 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, today
provided further detail from the positive top line results from its pivotal
Phase III field study G306 to evaluate the efficacy and safety of Grass MATA
MPL, the Group's short-course subcutaneous allergen-specific immunotherapy
(SCIT) candidate that aims to address the cause of symptoms of allergic
rhinoconjunctivitis due to grass pollen. The trial successfully met its
primary endpoint as previously announced on 14 November 2023.

 

An evaluation was conducted in both the EU and US to assess the impact of a
treatment regimen consisting of six pre-seasonal injections given over a span
of 14 weeks. The key findings from this evaluation are as follows:

 

·      The primary endpoint of the trial, "Combined Symptom &
Medication Score (CSMS) averaged over the peak pollen season", demonstrated a
statistically significant improvement of 20.3% (p=0.00024) for Grass MATA MPL
compared to placebo, providing evidence of a substantial reduction in daily
symptoms and use of relief medication among participants receiving Grass MATA
MPL

·      A highly statistically significant improvement in the
rhinoconjunctivitis quality of life questionnaire (RQLQ) (p=0.0003) was
observed during the peak season

·      The protective biomarker immunoglobulin (IgG4), measured during
the grass pollen season, showed a large increase of approximately five-fold
after treatment with Grass MATA MPL compared to placebo which achieved high
statistical significance (p<0.0001) consistent with data from the earlier
G309 exploratory field trial

·      555 subjects with allergic conjunctivitis and/or rhinitis were
randomised and 528 (95%) completed all six injections of Grass MATA MPL or
placebo. Demographics, allergic history and immunoglobulins were generally
well-balanced at baseline between the Grass MATA MPL and placebo groups. In
total, 278 and 277 patients received Grass MATA MPL and placebo, respectively.

 

As previously communicated, the treatment was well tolerated with no
unexpected safety signals. Further exploratory endpoint analyses (including an
extensive biomarker evaluation) of the G306 trial are now underway. Full
results, including secondary and exploratory endpoints, will be presented at
the upcoming European Academy of Allergy & Clinical Immunology conference
in June 2024 and submitted for peer-reviewed publication later this year. The
Group's preparation for the marketing authorisation application (MAA) is well
underway, with a planned submission in Q4 2024.

 

Manuel Llobet, CEO at Allergy Therapeutics, stated: "The findings announced
today further demonstrate the beneficial treatment effect of our Grass MATA
MPL immunotherapy candidate. Grass pollen, a common cause of seasonal allergy,
significantly impacts the lives of many people, necessitating the development
of new treatment options.

 

"The results of our G306 study, alongside the results of our earlier G309
exploratory field study, provide a strong and consistent data package for
progression to an MAA submission. This affords us the potential to provide a
unique offering to the market as the only Grass SCIT product registered
through the TAV programme in Germany. I would like to express my gratitude to
our team at Allergy Therapeutics and our partners at multiple trial sites and
countries for their exceptional work and dedication to this trial. A special
thank you goes to the patients who participated in our trial programme.
Without their involvement, we would not be able to bring these urgently needed
treatments to the market."

 

 

This announcement contains inside information for the purposes of Article 7 of
Regulatory (EU) No596/2014.

 

 

- ENDS -

 

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0) 20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

About Allergic Rhinitis

Allergic rhinitis and/or rhinoconjunctivitis is a type I allergic disease to
common aeroallergens such as pollen, mould spores and house dust mite residue.
Seasonal allergic rhinitis is most commonly caused by allergy to pollen from
tree, grasses or weeds, while perennial allergic rhinitis is most commonly
associated with allergy to dust mite residue, mould spores or animal dander

 

About Grass MATA MPL

Grass MATA MPL is being developed as a pre-seasonal subcutaneous immunotherapy
product for the treatment of allergic rhinitis and/or rhinoconjunctivitis.

 

Grass MATA MPL contains an extract of 13 grass pollens modified with
glutaraldehyde (allergoid) to reduce the reactivity with immunoglobulin E
(IgE) antibodies without a reduction in other important immunological
properties, such as T-cell reactivity. The allergoid is adsorbed to L-tyrosine
as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL), is
included as an adjuvant to increase the immunogenic effect of the
immunotherapy and to enhance the switch from an allergen specific helper
T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like immune response.

 

More information about the Phase III G306 Grass MATA MPL trial can be found on
ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home) under the identifier
NCT05540717 (https://clinicaltrials.gov/ct2/show/NCT05540717) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBCGDUBDGDGSL